Moteur de recherche d’entreprises européennes
Financement de l’UE (4 041 816 €) : Acides nucléiques pour l’édition génomique, l’immunothérapie et la modification de séquences épigénétiques Hor11/02/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Acides nucléiques pour l’édition génomique, l’immunothérapie et la modification de séquences épigénétiques
Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.
| Atdbio Ltd. | 303 173 € |
| BASECLICK GmbH | 252 788 € |
| Dublin City University | 824 053 € |
| Ecole Nationale Superieure de Chimie de Paris | 274 802 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 505 577 € |
| National Institute for Bioprocessing Research and Training Ltd. | 274 684 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 303 173 € |
| The University of Reading | 606 345 € |
| Uniwersytet Warszawski | 227 479 € |
| Ustav Organicke Chemie A Biochemie, AV CR, V.V.I. | 469 743 € |
https://cordis.europa.eu/project/id/861381
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.